NASDAQ:HURA TuHURA Biosciences Q3 2026 Earnings Date & Estimates $1.54 -0.12 (-7.23%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. TuHURA Biosciences is estimated to report Q3 2026 earnings on Friday, November 13, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 13, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from TuHURA Biosciences in Q3 2026TuHURA Biosciences is expected to post earnings of -$0.14 per share. In the same quarter a year earlier TuHURA Biosciences reported -$0.14 per share. TuHURA Biosciences last reported on August 14, 2026, posting -$0.14 per share and beating the -$0.1533 consensus estimate. TuHURA Biosciences has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.14Prior-Year EPS-$0.14Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.14 (Beat by +$0.0133)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report TuHURA Biosciences Q3 2026 Earnings FAQ When does TuHURA Biosciences report Q3 2026 earnings? TuHURA Biosciences (NASDAQ:HURA) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is TuHURA Biosciences' Q3 2026 earnings call? TuHURA Biosciences' Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for TuHURA Biosciences? Analysts expect TuHURA Biosciences to post earnings of -$0.14 per share for Q3 2026. TuHURA Biosciences Earnings HeadlinesTuHURA Biosciences, Inc. (NASDAQ:HURA) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsNovember 6, 2026 | americanbankingnews.comTuHURA Biosciences (HURA) Set to Post Earnings on FridayNovember 6, 2026 | americanbankingnews.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and ExpositionNovember 4, 2026 | prnewswire.comBrookline Capital Markets Estimates HURA FY2030 EarningsOctober 30, 2026 | americanbankingnews.comTuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated ...October 26, 2026 | finance.yahoo.comSee More TuHURA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email. Email Address About TuHURA BiosciencesTuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies. TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments. The company is advancing IFx-2 through clinical development and maintains a broader pipeline of immunotherapy programs. TuHURA is based in the United States and is focused primarily on clinical research and development rather than commercial products. Its therapies remain investigational and are subject to clinical testing and regulatory review before they can be marketed.View TuHURA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
